| Literature DB >> 31857579 |
Sayantan Jana1, Mei Hu1, Mengcheng Shen2, Zamaneh Kassiri3.
Abstract
Aortic aneurysm is an asymptomatic disease with dire outcomes if undiagnosed. Aortic aneurysm rupture is a significant cause of death worldwide. To date, surgical repair or endovascular repair (EVAR) is the only effective treatment for aortic aneurysm, as no pharmacological treatment has been found effective. Aortic aneurysm, a focal dilation of the aorta, can be formed in the thoracic (TAA) or the abdominal (AAA) region; however, our understanding as to what determines the site of aneurysm formation remains quite limited. The extracellular matrix (ECM) is the noncellular component of the aortic wall, that in addition to providing structural support, regulates bioavailability of an array of growth factors and cytokines, thereby influencing cell function and behavior that ultimately determine physiological or pathological remodeling of the aortic wall. Here, we provide an overview of the ECM proteins that have been reported to be involved in aortic aneurysm formation in humans or animal models, and the experimental models for TAA and AAA and the link to ECM manipulations. We also provide a comparative analysis, where data available, between TAA and AAA, and how aberrant ECM proteolysis versus disrupted synthesis may determine the site of aneurysm formation.Entities:
Mesh:
Year: 2019 PMID: 31857579 PMCID: PMC6923362 DOI: 10.1038/s12276-019-0286-3
Source DB: PubMed Journal: Exp Mol Med ISSN: 1226-3613 Impact factor: 8.718
Fig. 1Cross section of the aortic wall and its remodeling during physiological versus pathological remodeling. The tunica media is separated from the tunica intima by the internal elastic lamina, and from the tunica adventitia by the external elastic lamina. Intermittent layers of elastic fiber and smooth muscle cells make up the tunica media, while this region is also rich in proteoglycans and glycoproteins. During physiological remodeling, degradation of ECM proteins by MMPs (and other proteases) is balanced by newly synthesized ECM proteins, while tissue inhibitors of proteases (TIMPs) keep the proteolytic activity of MMPs under check. Excess ECM degradation, or impaired ECM renewal synthesis, along with smooth muscle cell death, lead to adverse ECM remodeling as observed in aortic aneurysm
The impact of genetic alterations of ECM-related genes on aortic aneurysm
| Mouse strain | Aneurysm model used | Phenotype | Ref. |
|---|---|---|---|
| CaCl2-induced TAA, AAA | Protection against AAA, TAA | ||
| Ang II infusion | Exacerbated aortic dilation, TAA | ||
| Cholesterol-rich diet | Reduced aneurysm formation | ||
| Intraluminal elastase-induced AAA | Protection against AAA | ||
| CaCl2-induced AAA | Protection against AAA | ||
| Wild-type/ | CaCl2-induced AAA | Reduced formation of AAA | |
| Cholesterol-rich diet and Ang II infusion | No changes observed | ||
| High-fat diet and Ang II infusion | Reduced aneurysm, dissection, and aortic rupture | ||
| Ang II infusion | Increased dilatation of the ascending aorta | ||
| SMC- or EC-specific | Adventitial elastase-induced TAA | Protection against TAA | |
| SMC-specific | Ang II + BAPN | Protection against TAA | |
| Ang II infusion | Protection against AAA | ||
| Intraluminal elastase-induced AAA | Reduced AAA | ||
| Intraluminal elastase-induced AAA | Reduced AAA | ||
| High cholesterol diet | No changes observed | ||
| High cholesterol diet | Protected against media destruction and aneurysm | ||
| CaCl2-induced AAA | Reduced AAA | ||
| SMC-specific | Aortic xenograft | Prevented AAA formation | |
| Ang II-induced AAA | Protection against AAA | ||
| Intraluminal elastase-induced AAA | Enhanced aneurysm | ||
| CaCl2-induced TAA | Enhanced aneurysm | ||
| SMC-specific | Aortic xenograft AAA | Prevented AAA degeneration and rupture | |
| CaCl2-induced AAA | Protection against AAA | ||
| Ang II infusion | Enhanced AAA | ||
| Ang II infusion | Exacerbated AAA | ||
| Spontaneous | Perinatal death | ||
| Spontaneous | Supravalvular aortic stenosis | ||
| Spontaneous | Perinatal death due to abolished elastogenesis | ||
| SMC-specific | Spontaneous | Spontaneous ascending and thoracic aortic aneurysm | |
| Spontaneous | Arteriopathy, aneurysm, and dissection | ||
| Spontaneous | Age-dependent aortic dissection and rupture | ||
| Spontaneous | Sudden death due to TAA, dissection, and rupture | ||
| Spontaneous | Spontaneous death after birth due to aortic rupture | ||
| Spontaneous | Spontaneous aortic dissection and rupture | ||
| Ang II infusion | Reduced AAA and rupture | ||
| SMC-specific | Spontaneous | Attenuated TAA compared with | |
| Ang II infusion | Attenuated TAA |
Fbln fibulin, Fbn fibrillin, Cat cathepsin, Bgn biglycan, Dcn decorin, Plat total plasminogen activator, Plau urokinase-plasminogen activator, Plg plasminogen, Pai plasminogen activator inhibitor, Gzmb granzyme B, Mmp matrix metalloproteinase, Apoe apolipoprotein E, Adam a disintegrin and metalloproteinase, Adamts ADAMs with thrombospondin motifs, Timp tissue inhibitor of metalloproteinases, Eln elastin, Col collagen, Lox lysyl oxidase, SMC smooth muscle cell, EC endothelial cell, Ang II angiotensin II
ECM protein mutations associated with hereditary aortic aneurysm in humans
| ECM gene | Identified genetic alterations | Syndrome/phenotype | Ref. |
|---|---|---|---|
| Missense mutations | Osteogenesis imperfecta; Ehlers–Danlos syndrome type 7A | ||
| Missense mutations | Osteogenesis imperfecta; Ehlers–Danlos syndrome type 7B | ||
| Multi-exon deletions | Ehlers–Danlos syndrome, type 4 | ||
| Mutations in exon 24, exon 25 | Hereditary angiopathy, nephropathy, and aneurysms | ||
| Nonsense mutations | X-linked Alport syndrome; TAA, AAA | ||
| Multiple point mutations | Supravalvular aortic stenosis; ascending aortic aneurysm and dissection | ||
| Missense mutations | Marfan syndrome; TAA | ||
| Mutations of intron 32, resulting in missplicing of exon 32 | Cutis laxa with aneurysm; TAA | ||
| Heterozygous mutations | Cutis laxa with aneurysm | ||
| Loss-of-function missense mutation | TAA and dissection | ||
| Mutations at the MH2 domain | Loeys–Dietz syndrome type 3 | ||
| Heterozygous mutations or microdeletions | Loeys–Dietz syndrome type 4 | ||
| Heterozygous mutations | Loeys–Dietz syndrome type 1 | ||
| Heterozygous mutations | Loeys–Dietz syndrome type 2 |